Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Interleukin-21 restrains tumor growth and induces a substantial increase in the number of circulating tumor-specific T cells in a murine model of malignant melanoma.

Petersen CC, Diernaes JE, Skovbo A, Hvid M, Deleuran B, Hokland M.

Cytokine. 2010 Jan;49(1):80-8. doi: 10.1016/j.cyto.2009.11.001.

PMID:
19962321
2.

Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.

Wack C, Kirst A, Becker JC, Lutz WK, Bröcker EB, Fischer WH.

Cancer Immunol Immunother. 2002 Oct;51(8):431-9.

PMID:
12202904
3.

Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.

Gold JE, Zachary DT, Osband ME.

Clin Immunol Immunopathol. 1994 Oct;73(1):115-22. Erratum in: Clin Immunol Immunopathol 1995 Jul;76(1 Pt 1):105. Retraction in: Clin Immunol Immunopathol. 1998 Jun;87(3):314.

PMID:
7923908
4.

Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.

Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.

In Vivo. 1999 May-Jun;13(3):199-204.

PMID:
10459491
5.

Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.

Saxton ML, Longo DL, Wetzel HE, Tribble H, Alvord WG, Kwak LW, Leonard AS, Ullmann CD, Curti BD, Ochoa AC.

Blood. 1997 Apr 1;89(7):2529-36.

6.

The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.

Palomares T, Bilbao P, Alonso-Varona A, Barberá-Guillem E.

Cancer Immunol Immunother. 1995 May;40(5):292-8.

PMID:
7600560
7.

Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F.

J Clin Invest. 1998 Jan 15;101(2):429-41.

9.
10.

Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.

Prévost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H.

J Immunol. 1998 Sep 1;161(5):2187-94.

11.

Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma.

Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M.

J Exp Ther Oncol. 2003 Jul-Aug;3(4):161-8.

PMID:
14567287
13.

Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.

Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O.

Mol Ther. 2002 May;5(5 Pt 1):609-16.

14.

Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.

Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE.

J Immunother Emphasis Tumor Immunol. 1993 Apr;13(3):153-65.

PMID:
8471590
15.

Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.

Galvan DL, O'Neil RT, Foster AE, Huye L, Bear A, Rooney CM, Wilson MH.

PLoS One. 2015 Oct 16;10(10):e0140744. doi: 10.1371/journal.pone.0140744.

16.

Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection.

Petersen CC, Petersen MS, Agger R, Hokland ME.

J Immunother. 2006 May-Jun;29(3):241-9.

PMID:
16699367
17.

Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.

Harada M, Matsuzaki G, Shinomiya Y, Kurosawa S, Ito O, Okamoto T, Takenoyama M, Sumitika H, Nishimura Y, Nomoto K.

Cancer Immunol Immunother. 1994 May;38(5):332-8.

PMID:
8162615
18.

Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells.

Palomares T, Alonso-Varona A, Alvarez A, Castro B, Calle Y, Bilbao P.

Clin Exp Metastasis. 1997 May;15(3):329-37.

PMID:
9174132
19.

Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.

Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tüting T.

Cancer Res. 2009 Aug 1;69(15):6265-74. doi: 10.1158/0008-5472.CAN-09-0579.

20.

Immunologic enhancement of B16 melanoma growth.

Ershler WB, Tuck D, Moore AL, Klopp RG, Kramer KE.

Cancer. 1988 May 1;61(9):1792-7.

Items per page

Supplemental Content

Support Center